Compare XRTX & ABTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XRTX | ABTS |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | Canada | Hong Kong |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 4.2M |
| IPO Year | 2018 | 2021 |
| Metric | XRTX | ABTS |
|---|---|---|
| Price | $0.97 | $1.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 346.0K | 8.6K |
| Earning Date | 11-16-2026 | 10-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $392.31 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $0.76 |
| 52 Week High | $3.60 | $9.03 |
| Indicator | XRTX | ABTS |
|---|---|---|
| Relative Strength Index (RSI) | 28.81 | 43.17 |
| Support Level | $0.37 | $1.14 |
| Resistance Level | $2.26 | $1.30 |
| Average True Range (ATR) | 0.22 | 0.06 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 2.73 | 14.36 |
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
Abits Group Inc is a bitcoin mining company. The Company operates self-owned and hosted bitcoin mining facilities in Tennessee, United States.